BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-46@catalystbrief.girapphe.com
DTSTAMP:20261117T061550Z
LAST-MODIFIED:20261117T061550Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Bristol-Myers Squibb — Nivolumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Nivolumab Combined With 
 Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Can
 cer.\nSource: https://clinicaltrials.gov/study/NCT03873402\nhttps://cataly
 stbrief.girapphe.com/e/46?lang=en\nNot investment advice. Dates may change
 .
URL:https://catalystbrief.girapphe.com/e/46?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
